P. Bourquelot

发表

Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

R. Bataille, P. Moreau, V. Leblond, 1998, British journal of haematology.

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

H. Goldschmidt, S. Lonial, R. Vij, 2012, Leukemia & lymphoma.

Expression of the Alpha/Beta and Gamma/ Delta T-cell Receptors in 57 Cases of Peripheral T-cell Lymphomas Identification of a Subset of y/6 T-ceII Lymphomas

P. Gaulard, C. Haioun, J. P. Couédic, 2007 .

Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation

N. Schmitz, D. Hasenclever, A. Nagler, 1998, Bone Marrow Transplantation.

MLL cleavage occurs in approximately 5% of de novo acute myeloid leukemia, including in patients analyzed before treatment induction.

E. Macintyre, T. Smetsers, R. Rimokh, 1997, Blood.

Clinical and biological analysis of peripheral T-cell lymphomas: a single institution study.

P. Gaulard, F. Roudot-thoraval, C. Haioun, 1992, Leukemia & lymphoma.

Expression of the alpha beta and gamma delta T-cell receptors in peripheral T-cell lymphomas.

P. Gaulard, C. Haioun, F. Reyes, 1990, Nouvelle revue francaise d'hematologie.

Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM).

S. Lonial, J. S. San Miguel, M. Mateos, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

H. Goldschmidt, S. Lonial, R. Vij, 2008 .

Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas.

P. Gaulard, C. Haioun, F. Reyes, 1990, The American journal of pathology.

TAL1 expression does not occur in the majority of T‐ALL blasts

J. Cayuela, E. Macintyre, J. Strominger, 1998, British journal of haematology.

Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization

E. Macintyre, M. Vekemans, I. Radford‐Weiss, 1998, Genes, chromosomes & cancer.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

P. Richardson, O. Sezer, S. Mu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.

N. Brousse, M. Mamzer-Bruneel, O. Hermine, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Homing Receptor α4β7 Integrin Expression Predicts Digestive Tract Involvement in Mantle Cell Lymphoma

E. Macintyre, F. Geissmann, N. Brousse, 1998 .

A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma.

D. Siegel, P. Richardson, O. Sezer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

G. Ossenkoppele, S. Goldberg, G. Alimena, 2008 .

A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

L. Akard, A. Skotnicki, F. Guilhot, 2008 .

A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.

Kenneth C. Anderson, Jesús F. San-Miguel, M. Boccadoro, 2008 .

Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

S. Lonial, T. Facon, J. San-Miguel, 2010 .

PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.

H. Einsele, S. Lonial, W. Jędrzejczak, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

K. Anderson, D. Siegel, O. Sezer, 2010 .

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

M. Dimopoulos, H. Einsele, S. Lonial, 2011 .

Treatment and prognosis of post-transplant lymphoproliferative disease.

C. Legendre, M. Mamzer-Bruneel, O. Hermine, 1997, Annals of transplantation.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

P. Richardson, O. Sezer, S. Mu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.